The first revenue outlook for asundexian, designed to prevent thrombosis and strokes, shows Bayer's confidence that it can replace revenue from one of its pharmaceutical best-sellers, Xarelto, which is set to lose protection from key European patents in 2026.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Zk8GQNo
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Bayer flags new blood thinner as $5 bln-plus opportunity
https://ift.tt/gSiDT9O
No comments:
Post a Comment